Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease (COPD-01)
Primary Purpose
Chronic Obstructive Pulmonary Disease, Pulmonary Emphysema
Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Stem cells stimulation
stem cells collection
stem cells infusion
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring Chronic Obstructive Pulmonary Disease, Emphysema, Cell therapy, Bone marrow mononuclear cells, stem cells
Eligibility Criteria
Inclusion Criteria:
- diagnosis of severe chronic obstructive pulmonary disease
- ineffective clinical treatment
- limited life expectancy
- limitations in daily physical activity
- possibility of pulmonary rehabilitation physiotherapy
- acceptable nutritional status
- acceptable cardiac function
- at least six months smoking cessation
- family support
- modified medical research council dyspnea scale stage > 3
Exclusion Criteria:
- pulmonary or extra-pulmonary infection
- severe coronary disease and/or ventricular dysfunction
- significant kidney or liver disease
- immunosuppressive disease
- active smoker
- cancer
- psychosocial problems
- established medical protocol
- family rejection
- pregnancy
Sites / Locations
- Laboratório de Genética Humana e Terapia Celular
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
pre-procedure
post-procedure
Arm Description
emphysema patients evaluated prior to the stem cells infusion
emphysema patients evaluated 30 days after the stem cells infusion
Outcomes
Primary Outcome Measures
Forced Vital Capacity (FVC)
A pulmonary function test that measures the volume and speed of the inhalated air.
Forced Expiratory Volume (FEV1)
A pulmonary function test that measures the volume and speed of the exhaled air.
Vital Capacity - VC
A pulmonary function test that measures the volume and speed of the inhalated and exhaled air.
Secondary Outcome Measures
Arterial Blood Gases Test - Pa O2
presence of oxygen in the blood gases.
Arterial Blood Gases Test - Pa CO2
presence of CO2 in the arterial blood.
Full Information
NCT ID
NCT01110252
First Posted
April 20, 2010
Last Updated
February 22, 2012
Sponsor
UPECLIN HC FM Botucatu Unesp
Collaborators
Laboratório de Genética Humana e Terapia Celular, Unesp - Assis, Instituto de Molestias Cardiovasculares
1. Study Identification
Unique Protocol Identification Number
NCT01110252
Brief Title
Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease
Acronym
COPD-01
Official Title
Unicentric Study Protocol of Cell Therapy in Chronic Obstructive Pulmonary Disease
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
November 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
UPECLIN HC FM Botucatu Unesp
Collaborators
Laboratório de Genética Humana e Terapia Celular, Unesp - Assis, Instituto de Molestias Cardiovasculares
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether the cell therapy with bone marrow mononuclear cells is safe in the treatment of chronic obstructive pulmonary disease, specifically the pulmonary emphysema.
Detailed Description
The main feature of the pulmonary emphysema, included in range of the Chronic Obstructive Pulmonary Disease (COPD), is the airflow obstruction resulting from the destruction of the alveolar walls distal to the terminal bronchiole, without significant pulmonary fibrosis. The existing clinical approaches has contributed to the enlargement and amelioration of the emphysema patients life quality, although no effective or curative treatment has been achieved. The surgical treatment, on the other hand, involves complex procedures and, in the specific case of lung transplantation, a lack of donors.
Considering these aspects, several experimental models have been proposed aiming to increase knowledge about the pathophysiological processes and enable new clinical approaches to the pulmonary emphysema. The cell therapy, briefly described as the use of cells in disease treatment, presents itself as a promising therapeutic approach with great potential applicability in degenerative pulmonary diseases. In this way, it is intended in this project, the proposition of a protocol to evaluate the safety of cell therapy with pool of mononuclear cells from bone marrow in patients with clinical and laboratory diagnosis of pulmonary emphysema in advanced stage (stage IV dyspnea).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Obstructive Pulmonary Disease, Pulmonary Emphysema
Keywords
Chronic Obstructive Pulmonary Disease, Emphysema, Cell therapy, Bone marrow mononuclear cells, stem cells
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
pre-procedure
Arm Type
Active Comparator
Arm Description
emphysema patients evaluated prior to the stem cells infusion
Arm Title
post-procedure
Arm Type
Experimental
Arm Description
emphysema patients evaluated 30 days after the stem cells infusion
Intervention Type
Drug
Intervention Name(s)
Stem cells stimulation
Other Intervention Name(s)
Filgrastin - ACHÉ Laboratories.
Intervention Description
Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
Intervention Type
Procedure
Intervention Name(s)
stem cells collection
Other Intervention Name(s)
bone marrow harvest
Intervention Description
pullout of 200ml of bone marrow through the puncture of the iliac crest
Intervention Type
Genetic
Intervention Name(s)
stem cells infusion
Other Intervention Name(s)
adult stem cell infusion
Intervention Description
slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
Primary Outcome Measure Information:
Title
Forced Vital Capacity (FVC)
Description
A pulmonary function test that measures the volume and speed of the inhalated air.
Time Frame
baseline and 30 days after procedure
Title
Forced Expiratory Volume (FEV1)
Description
A pulmonary function test that measures the volume and speed of the exhaled air.
Time Frame
baseline and 30 days after procedure
Title
Vital Capacity - VC
Description
A pulmonary function test that measures the volume and speed of the inhalated and exhaled air.
Time Frame
baseline and 30 days after the procedure
Secondary Outcome Measure Information:
Title
Arterial Blood Gases Test - Pa O2
Description
presence of oxygen in the blood gases.
Time Frame
baseline and 30 days after procedure
Title
Arterial Blood Gases Test - Pa CO2
Description
presence of CO2 in the arterial blood.
Time Frame
baseline and 30 days after the procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
72 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosis of severe chronic obstructive pulmonary disease
ineffective clinical treatment
limited life expectancy
limitations in daily physical activity
possibility of pulmonary rehabilitation physiotherapy
acceptable nutritional status
acceptable cardiac function
at least six months smoking cessation
family support
modified medical research council dyspnea scale stage > 3
Exclusion Criteria:
pulmonary or extra-pulmonary infection
severe coronary disease and/or ventricular dysfunction
significant kidney or liver disease
immunosuppressive disease
active smoker
cancer
psychosocial problems
established medical protocol
family rejection
pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
João T Ribeiro-Paes, PhD MD
Organizational Affiliation
geneticist
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Aldemir Bilaqui, MD
Organizational Affiliation
surgeon
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Oswaldo T Greco, MD
Organizational Affiliation
cardiologist
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Milton A Ruiz, MD
Organizational Affiliation
hematologist
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
José D Araújo, MD
Organizational Affiliation
surgeon
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Mario R Lago, Ms
Organizational Affiliation
technician
Official's Role
Study Chair
Facility Information:
Facility Name
Laboratório de Genética Humana e Terapia Celular
City
Assis
State/Province
São Paulo
ZIP/Postal Code
19.806-900
Country
Brazil
12. IPD Sharing Statement
Citations:
PubMed Identifier
24287082
Citation
Ribeiro-Paes JT, Stessuk T, Marcelino M, Faria C, Marinelli T, Ribeiro-Paes MJ. A protocol proposition of cell therapy for the treatment of chronic obstructive pulmonary disease. Rev Port Pneumol. 2014 Mar-Apr;20(2):84-91. doi: 10.1016/j.rppneu.2013.06.008. Epub 2013 Nov 26. English, Portuguese.
Results Reference
derived
PubMed Identifier
21311694
Citation
Ribeiro-Paes JT, Bilaqui A, Greco OT, Ruiz MA, Marcelino MY, Stessuk T, de Faria CA, Lago MR. Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon Dis. 2011 Jan 1;6:63-71. doi: 10.2147/COPD.S15292.
Results Reference
derived
Learn more about this trial
Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease
We'll reach out to this number within 24 hrs